Genohco제노코
361390 · KOSDAQ · ₩361390 · 제노코
₩9,860▼ ₩40 (0.40%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩11B | ₩12B | ₩17B | ₩18B | ₩14B | ₩11B | ₩14B | ₩18B |
| Cost of sales | ₩10B | ₩12B | ₩16B | ₩16B | ₩14B | ₩10B | ₩12B | ₩18B |
| Gross profit | ₩523M | ₩83M | ₩885M | ₩1.6B | −₩233M | ₩263M | ₩1.4B | −₩168M |
| Operating income | −₩696M | −₩1.2B | −₩195M | ₩378M | −₩1.4B | −₩872M | ₩359M | −₩1.2B |
| Net income | ₩1B | −₩816M | −₩2.4B | ₩1.2B | ₩172M | −₩1B | −₩1.4B | −₩1.4B |
| Net income to shareholders | ₩1B | −₩816M | −₩2.4B | ₩1.2B | ₩172M | −₩1B | −₩1.4B | −₩1.4B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₩91B | ₩89B | ₩88B | ₩94B | ₩82B | ₩85B | ₩87B | ₩100B |
| Current assets | ₩60B | ₩59B | ₩56B | ₩63B | ₩51B | ₩54B | ₩57B | ₩70B |
| Cash and equivalents | ₩35B | ₩35B | ₩30B | ₩33B | ₩22B | ₩31B | ₩32B | ₩44B |
| Total liabilities | ₩25B | ₩24B | ₩36B | ₩43B | ₩50B | ₩52B | ₩53B | ₩65B |
| Current liabilities | ₩25B | ₩24B | ₩17B | ₩23B | ₩31B | ₩33B | ₩35B | ₩45B |
| Borrowings | ₩4.3B | ₩4.7B | ₩18B | ₩18B | ₩18B | ₩17B | ₩17B | ₩25B |
| Total equity | ₩66B | ₩65B | ₩52B | ₩51B | ₩32B | ₩33B | ₩34B | ₩35B |
| Shareholders' equity | ₩66B | ₩65B | ₩52B | ₩51B | ₩32B | ₩33B | ₩34B | ₩35B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | ₩94M | ₩4.5B | −₩3.4B | −₩7B | −₩8.3B | −₩1.1B | −₩1.9B | ₩10B |
| Capital spending | ₩197M | ₩48M | ₩237M | ₩395M | ₩127M | ₩449M | ₩1.3B | ₩1.9B |
| Free cash flow | −₩103M | ₩4.5B | −₩3.7B | −₩7.4B | −₩8.4B | −₩1.5B | −₩3.3B | ₩8.2B |
| Dividends paid | — | — | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Genohco / 제노코 / 361390 / KRX:361390
Source: KRX statistical information